For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease ( ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)
As bacteria break down this food, they can produce hydrogen sulfide gas, leading to burps that smell like rotten eggs
Zantac 360 is available but it contains famotidine as its active ingredient
Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease or health condition
Wegovy is another semaglutide medication that acts identically to Ozempic and is specifically marketed for weight loss